Acorda Therapeutics, Inc. Profile Avatar - Palmy Investing

Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis…

Drug Manufacturers - Specialty & Generic
US, Ardsley [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Acorda Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ACOR's Analysis
CIK: 1008848 CUSIP: 00484M106 ISIN: US00484M7002 LEI: - UEI: -
Secondary Listings
ACOR has no secondary listings inside our databases.